Proviron (Mesterolone) — Dosing, Cycles, Half-Life & Side Effects
Proviron (Mesterolone) is an oral anabolic-androgenic steroid with a half-life of 12 hours. Mesterolone (1α-methyl-DHT) oral. NOT 17α-alkylated — therefore no cholestatic hepatotoxicity profile of 17αα orals. Approved in EU/UK (not US) for male infertility/hypogonadism. Binds SHBG (raising free testosterone) and competes with E2 at AR. Minimal anabolic effect; primarily used as anti-estrogenic adjunct. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.
Quick Facts
| Class | Orals |
|---|---|
| Half-life | 12 hours |
| Detection window | 42 days |
| Aromatization | No |
| Hepatotoxicity | None |
| Suppression | 2/10 |
| 17α-alkylated | No |
| Administration | oral |
Typical Dosing Ranges
Common dose range: 25-100mg/day
Cycle length: 8-12 weeks
Time to steady state: ~2.5 days
Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.
Stacking Considerations
- No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.
PCT Requirements
- Depot clearance estimate: ~3 days post-last-dose before SERM start (5 × apparent depot half-life of 12h).
- Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
- Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.
Side Effect Profile
- Limited anabolic effects
- Hair loss risk
- May worsen prostate
- Not effective for mass
Known Interactions
No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.
Related compounds
Monitoring (Bloodwork & Vitals)
- Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
- Lipid panel (total cholesterol, HDL, LDL, triglycerides)
- CBC (hemoglobin, hematocrit — watch for erythrocytosis)
- Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
- Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)
Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.
Frequently Asked Questions
What is the half-life of Proviron (Mesterolone)?
Proviron (Mesterolone) has a half-life of approximately 12 hours. Clearance estimate: 12h × 5 = 60h = 2.5 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.
What is the typical dose range for Proviron (Mesterolone)?
Commonly reported ranges for Proviron (Mesterolone): 25-100mg/day. Cycle length: 8-12 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.
Does Proviron (Mesterolone) suppress natural testosterone?
Proviron (Mesterolone) causes minimal suppression of the HPTA axis (score 2/10). PCT may still be advisable depending on stack and duration.
Does Proviron (Mesterolone) aromatize to estrogen?
Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.
What is Proviron (Mesterolone) typically used for?
Proviron (Mesterolone) is commonly used for: Anti-estrogen, Libido support, Cutting cycles. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.
Citations
- Pharmaceutical reference. 2004. Mesterolone prescribing data — Half-life 12-13 hours for mesterolone
- PMID: 689818. 1978. Clinical study — Does not significantly influence plasma FSH, LH, or testosterone at therapeutic doses
- Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
- Gerris J, Comhaire F, Hellemans P et al.. 1991. Fertil Steril — Double-blind placebo-controlled RCT: 150 mg/day × 12 months in 52 men with idiopathic oligoasthenospermia — documents long-term safety at upper clinical dose
- Niedfeldt MW. 2018. Curr Sports Med Rep — 1α-methyl modification (mesterolone) does NOT produce 17α-alkylation-type hepatic clearance impairment; supports 'None' rating rather than 'Low'
- Albertsdóttir AD, Van Gansbeke W, Van Eenoo P, Polet M. 2023. Drug Test Anal — Sulphated metabolite detection of mesterolone for anti-doping; consistent with ~12h plasma half-life of parent compound
- Trost LW, Mulhall JP. Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials. J Sex Med. 2016. PMID: 27209182
Disclaimer
StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Proviron (Mesterolone). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.